The alliance combines Origenis' capabilities in compound design, chemical synthesis, and screening with the collaborator’s applied biology, pharmacology, and development expertise in therapeutics.
During the long standing collaboration, Origenis successfully employed its proprietary small molecule discovery platform MOREsystem® to design, synthesize, and characterize novel molecules acting against different targets. Under the extended agreement, Origenis will deliver development candidates with defined properties for certain targets.
Dr. Michael Thormann, Managing Director at Origenis said: “This new agreement underlines the quality of the compounds transferred in the past and the power of our technology platform as well as our interdisciplinary approach and expertise applied to development compounds and commitment of our company in the small molecule drug sector.”
Under the terms of the agreement, the collaborator will receive rights to develop products against defined molecular targets for any indication. Origenis will receive research payments and is eligible for certain development milestones and also royalties on sales.